Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <scp>STEP</scp> 1 trial extension
2022 · Diabetes Obesity and Metabolism · 808 citations
https://doi.org/10.1111/dom.14725
K
Kristian Kandler
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
36
Papers
2.3K
Citations
14
h-index
16
i10-index
Kristian Kandler is an academic researcher from Novo Nordisk (Denmark). The author has contributed to research in topics: Diabetes Treatment and Management & Metabolism, Diabetes, and Cancer & Cardiac, Anesthesia and Surgical Outcomes. The author has an h-index of 14, co-authored 31 publications.
ORCID: 0000-0003-0686-0549Papers by this author
worksTwo-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
2022 · Nature Medicine · 718 citations
https://doi.org/10.1038/s41591-022-02026-4
Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: <scp>STEP</scp> 5
2023 · Obesity · 94 citations
https://doi.org/10.1002/oby.23673
Higher arterial pressure during cardiopulmonary bypass may not reduce the risk of acute kidney injury
2019 · Journal of Cardiothoracic Surgery · 31 citations
https://doi.org/10.1186/s13019-019-0929-4
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial
2025 · The Lancet Diabetes & Endocrinology · 17 citations
https://doi.org/10.1016/s2213-8587(25)00226-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat